top of page

Optional Sessions

Bookings for these optional sessions can be made via the registration form.

If you have already registered and would like to book, please email register@ccm.com.au

Where in the world does Nivolumab+Relatlimab fit?

Personalised treatment decisions in first line metastatic melanoma 
Interactive debate, blinded cases, you decide the win
ner

Sponsored by Bristol-Myers Squibb Australia
 

Date: Friday, March 24, 2023
Time: 12:30 - 13:15
Lunch provided

On behalf of the Steering Committee, Bristol Myers Squibb Australia is delighted to invite you to a debate during a lunchtime symposium session at the Australasian Melanoma Conference 2023. You may not be there in person, but no need to miss out on hearing their expert insights on the place of various immunotherapies and their combinations for first line metastatic melanoma treatment.

Treatment choices for advanced melanoma in the era of Nivolumab+Relatlimab, including the impact of BRAF mutation status, anatomical sites of disease and patient factors will be debated by the experts. 

Steering Committee and Speakers:
Prof Victoria Atkinson, Medical Oncologist, Princess Alexandra Hospital, QLD (Steering Committee Member & Speaker)
A/Prof Matteo Carlino, Medical Oncologist, Westmead & Blacktown Hospitals, Melanoma Institute Australia, NSW (Steering Committee Member & Speaker)
A/Prof Rachel Roberts-Thomson, Medical Oncologist, The Queen Elizabeth Hospital, SA (Speaker)

Optimising care and treatment for BRAF-mut melanoma patients

Session sponsored by Pierre Fabre

Date: Saturday, March 25, 2023

Time: 07:30 - 08:45

A deep dive into the latest published data on BRAF/MEK inhibitors & the key clinical challenges managing patients with advanced BRAF-mutant melanoma facing us today.

Chair: Prof Georgina Long, Sydney
Speaker: Prof Reinhard Dummer, Zurich (Switzerland)
Panel: A/Prof Andrew Haydon, Dr Megan Lyle

Breakfast provided

Dermoscopy Workshop

Hosted by AMC

Date: Saturday, March 25, 2023

Time: 07:30 - 08:45

Professor Harald Kittler is an internationally recognised dermatologist and a world expert in the field of dermoscopy in the diagnosis of pigmented skin lesions. Professor Cliff Rosendahl has written extensively on the diagnosis of pigmented skin lesions and the use of dermoscopy.  With their presence at the Australasian Melanoma Conference we have the opportunity to provide a workshop focussed on the practical issues around the use of dermoscopy. 


This will be a 75 minute practical guide to Dermoscopy of pigmented skin lesions. 

Symposium: A Practical Guide to Sentinel Node Biopsy

Hosted by AMC

Date: Saturday, March 25, 2023

Time: 07:30 - 08:45

Sentinel node biopsy has become an essential procedure for the surgeon involved with treating patients with advanced primary melanoma. At the Australasian Melanoma Conference there will be the presence of national and international experts involved in sentinel node biopsy, as well as surgeons experienced in the techniques in regional and metropolitan centres.  We plan to use this expertise to run a session focusing on the practical issues around the interpretation of lymphoscintigraphy and the sentinel node biopsy procedure. 


The session run for 75 minutes.  


Participants: 
 

Chair: Professor Mark Smithers 


Faculty: 
Dr Kevin London, Nuclear Physician / Radiologist, Sydney  – practical guide to interpretation of lymphoscintigraphy and Single-photon emission computered tomography (SPECT/CT).


Associate Professor Alex van Akkooi (Metropolitan) – Surgical Oncologist, Melanoma Institute Australia, Sydney.  – Practical tips to identify and find the sentinel node


Dr David Ryan, Lismore. Surgeon (Regional) – Practical issues for the regional surgeon   


Panel Discussion with examples of cases for discussion. 

Genetic counselling for primary melanoma

Restricted to 30 participants

Date: Saturday, March 25, 2023

Time: 08:30 - 10:30

Chair: Dr Aideen McInerney-Leo

One in ten melanoma patients will have an affected first degree relative and 10-20% of those will have a significant family history. Over a dozen genes have been identified in association with familial melanoma and 90% of cases that test positive will carry a mutation in CDKN2A. Recent systematic reviews show that genetic testing for hereditary melanoma is not associated with any psychological distress. Furthermore, there is evidence of improved primary and secondary preventative behaviours following testing. In addition, identifying a causal mutation in an affected family member allows for genetic testing in unaffected family members, to ensure that they receive appropriate screening to improve early detection.

 

Using brief didactic sessions, observational and participatory role plays, counselling aides and example testing/results forms, this workshop will empower clinicians to:

  • Advance pedigree taking and assessment skills

  • Increase confidence at evaluating personal and family history for risk assessment

  • Understand the components which need to be addressed in a pre-test session

  • Be familiar with how to order genetic testing for melanoma 

  • Understand the possible post-test result types and how to explain them

  • Recognise where and when to refer to clinical genetics’ services 

Hot Topics in Melanoma 

Sponsored by MSD

Date: Saturday, March 25, 2023

Time: 12:30 - 13:45

Details to come 

bottom of page